

**Certificate of Mailing or Transmission**

I, the undersigned, hereby certify that this correspondence along with other possible documents has been deposited with the U.S. Postal Service by express mail, postage pre-paid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 and having express mail number \_\_\_\_\_, or facsimile transmitted to the U.S. Patent and Trademark Office or electronically transmitted to the USPTO through its own EFS filing system on March 23, 2009.

Typed Name: Kevin D. McCarthy  
Date: March 23, 2009

Patent 0-06-225/16799/US/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor: Haj-Yehia, Abdullah I.  
Serial no.: 10/532,390  
Filed: October 24, 2003  
Title: STEROID COMPOUNDS COMPRISING SUPEROXIDE DISMUTASE  
MIMIC GROUPS AND NITRIC OXIDE DONOR GROUPS, AND  
THEIR USE IN THE PREPARATION OF MEDICAMENTS  
Examiner: Sara Clark  
Art Unit: 4121  
Confirmation 8417

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

**RESTRICTION RESPONSE**

This response is in reply to the office action mailed on January 7, 2009. Attached with this response is a petition for an extension of time of two months and appropriate fees.

**Restrictions**

In order to comply with the Examiner's request for restriction, it is confirmed that claims 31-48, belonging to Examiner's Group II, are now elected, with traverse. The applicant would be ready to restrict the compounds of formula (4) in claim 31, without prejudice, to multifunctional steroid compound whose R<sup>7</sup> is a substituted N-oxide free radical.

According to the Applicant's understanding, the Examiner requests to define a specific compound and a specific medical condition, in order to ease the search burden.


Although traversing the requirement, the following specific compound is provided: 11,17,21-trinitrato-16-DOXYL-dexamethasone, compound of which synthesis is shown in Example 11 on page 93. The compound falls into the ambit of general formula (4) of claim 31, where R<sup>2</sup> is NO donor -ONO<sub>2</sub>, R<sup>3</sup> is -CH<sub>3</sub>, R<sup>4</sup> is halogen -F, R<sup>5</sup> is NO donor -ONO<sub>2</sub>, R<sup>6</sup> is =O, R<sup>6A</sup> is not present, and R<sup>7</sup> is substituted N-oxide free radical being 5-membered ring, substituted as follows: 1-nitromethyl, 2-nitroxide, 3-dimethyl, 5-oxo. The structure is also clearly seen in formula IVc on page 52.

The following specific disease or condition to be treated, of all recited in claim 48, is provided as requested by the Examiner: "acute and chronic inflammatory conditions".

Novelty and request for rejoicing method claims

The Examiner cites Garvey et al. (US RE37,116 E) as providing a substituted steroid with an NO-donor, so depriving some of originally claimed structures of novelty. However, Garvey's structures do not comprise nitroxide radicals, and therefore elected compound of claim 31 with nitroxide free radical in R<sup>7</sup> would be novel and unobvious, and the elected compound would link Group II and III defined by the Examiner, which group would so form a single inventive concept.

Respectfully submitted

  
Kevin D. McCarthy  
Reg. No. 35,278

Roach, Brown, McCarthy & Gruber, P.C.  
1620 Liberty Building - 420 Main Street  
Buffalo, New York 14202